As momentum stocks suffer a sharp sell-off, value names are back in play.
Veteran Senior Biotechnology Analyst Charles Duncan of Piper Jaffray & Co. sees platform companies as the perfect way to play a consolidating market. We've had a big run in biotech, and
Billions of dollars have been spent chasing molecular targets in neurological diseases that now appear to be worthless. Effective therapies remain rare. But the market is enormous—and low
Company chart and information is provided by TradingView based on 15-minute-delayed data.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
| Website: | www.acadia-pharm.com |
| Email: | ir@acadia-pharm.com |
| Main Phone: | +1 858 558-2871 |
| Address: | 12830 El Camino Real |
| Address 2: | Suite 400 |
| State: | CA |
| City / Town: | San Diego |
| Country: | US |
| Postal Code: | 92130 |
| Exchange: | NGS |
| CEO: | Stephen R. Davis |
| Employees: | 601 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
As momentum stocks suffer a sharp sell-off, value names are back in play.
Veteran Senior Biotechnology Analyst Charles Duncan of Piper Jaffray & Co. sees platform companies as the perfect way to play a consolidating market. We've had a big run in biotech, and
Billions of dollars have been spent chasing molecular targets in neurological diseases that now appear to be worthless. Effective therapies remain rare. But the market is enormous—and low
It’s been a big year for biotech. Heck, it’s been a big year for most of the health care sector, but biotech’s been among the biggest gainers across the entire market, with the
Biotech stocks continued a rough week on Wednesday, with the iShares Nasdaq Biotechnology Fund ($IBB) down more than 2.5 percent in early trading, and off by almost 9 percent since Monday. This
Wednesday’s momentum on Wall Street was maintained throughout Thursday on news that the Department of Labor’s disappointing jobless claims figure from last Friday was revised from 388,000 down
ACADIA Pharmaceuticals (ACAD) was up 55.60 percent on Thursday, with shares trading as for as much as $12.40, after Wednesday’s closing price of $7.97.ACADIA makes drugs that treat neurological
At www.ValuEngine.com we show that the Medical sector 10.1% overvalued with the Medical Biomed/Genetics 11.9% overvalued. All 14 stocks in today’s table have complete ValuEngine data and have
The Dow Jones Industrial Average rebounded to 13,329.44 then consolidated during Fed Chief Bernanke’s press conference dipping into the red at 13,239.65 but staying above its 50-day and 200-day
Investor’s first read - Brooksie’s edge before the openFriday, June 15, 2012 8:21 a.m. ETDJIA: 12,651.91S&P 500: 1329.10Nasdaq Comp.: 2836.33Russell 2000:
| Last Price N/A | Change $ N/A | Change % N/A | Tick N/A |
| Bid N/A | Bid Size N/A | Ask N/A | Ask Size N/A |
| Open N/A | High N/A | Low N/A | Prev Close N/A |
| Last Trade | Volume N/A | 52 Wk Hi N/A | 52 Wk Low N/A |
| Market Cap N/A | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares N/A | EPS (TTM) N/A | PE Ratio N/A | Exchange N/A |
© 2022 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
